收稿日期: 2022-11-11
网络出版日期: 2023-04-23
基金资助
国家重点研发计划(2022YFC2503800);国家自然科学基金(81971213);国家自然科学基金(81671291);四川大学华西医院临床研究孵化项目(22HXFH022)
张天羽, 周东, 洪桢 . 《儿童抗NMDAR脑炎治疗的国际共识推荐》解读[J]. 诊断学理论与实践, 2022 , 21(06) : 677 -683 . DOI: 10.16150/j.1671-2870.2022.06.003
| [1] | Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma[J]. Ann Neurol, 2005, 58(4):594-604. |
| [2] | Dalmau J, Tüzün E, Wu H Y, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J]. Ann Neurol, 2007, 61(1):25-36. |
| [3] | 中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组. 中国自身免疫性脑炎诊治专家共识(2022年版)[J]. 中华神经科杂志, 2022, 55(9):931-949. |
| [3] | Chinese Society of Neuroinfectious Diseases and Cerebrospinal Fluid Cytology. Chinese expert consensus on the diagnosis and management of autoimmune encephalitis (2022 edition)[J]. Chin J Neurol, 2022, 55(9):931-949. |
| [4] | Graus F, Titulaer M J, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis[J]. Lancet Neurol, 2016, 15(4):391-404. |
| [5] | 中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50(2):91-98. |
| [5] | Neurology Branch of Chinese Medical Association. Chinese expert consensus on the diagnosis and management of autoimmune encephalitis[J]. Chin J Neurol, 2017, 50(2):91-98. |
| [6] | Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient[J]. Neurol Neuroimmunol Neuroinfl-amm, 2020, 7(2):e663. |
| [7] | Ho A C C, Mohammad S S, Pillai S C, et al. High sensitivity and specificity in proposed clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis[J]. Dev Med Child Neurol, 2017, 59(12):1256-1260. |
| [8] | Suppiej A, Nosadini M, Zuliani L, et al. Plasma exchange in pediatric anti-NMDAR encephalitis: A systematic review[J]. Brain Dev, 2016, 38(7):613-622. |
| [9] | Eyre M, Hacohen Y, Lamb K, et al. Utility and safety of plasma exchange in paediatric neuroimmune disorders[J]. Dev Med Child Neurol, 2019, 61(5):540-546. |
| [10] | Mo Y, Wang L, Zhu L, et al. Analysis of Risk Factors for a Poor Prognosis in Patients with Anti- N-Methyl-D-Aspartate Receptor Encephalitis and Construction of a Prognostic Composite Score[J]. J Clin Neurol, 2020, 16(3):438-447. |
| [11] | Xu X, Lu Q, Huang Y, et al. Anti-NMDAR encephalitis: A single-center, longitudinal study in China[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 7(1):e633. |
| [12] | Lee W J, Lee S T, Shin Y W, et al. Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis[J]. Neurotherapeutics, 2021, 18(1):474-487. |
| [13] | Yang X Z, Zhu H D, Ren H T, et al. Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study[J]. Chin Med J (Engl), 2018, 131(2):156-160. |
| [14] | Scheibe F, Prüss H, Mengel A M, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis[J]. Neurology, 2017, 88(4):366-370. |
| [15] | Titulaer M J, Mccracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol, 2013, 12(2):157-165. |
| [16] | Dale R C, Brilot F, Duffy L V, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease[J]. Neurology, 2014, 83(2):142-150. |
| [17] | Gong X, Chen C, Liu X, et al. Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8(2):e958. |
| [18] | Nosadini M, Granata T, Matricardi S, et al. Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis[J]. Dev Med Child Neurol, 2019, 61(9):1101-1107. |
| [19] | Hardy D. Autoimmune Encephalitis in Children[J]. Pediatr Neurol, 2022, 132:56-66. |
/
| 〈 |
|
〉 |
